Advocate

RSS

imidacloprid / moxidectin

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Advocate. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Advocate.

For practical information about using Advocate, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 12/03/2018

Authorisation details

Product details
Name
Advocate
Agency product number
EMEA/V/C/000076
Active substance
  • imidacloprid
  • moxidectin
International non-proprietary name (INN) or common name
imidacloprid / moxidectin
Species
  • Ferrets
  • Dogs
  • Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP54AB52
Publication details
Marketing-authorisation holder
Bayer Animal Health GmbH
Revision
19
Date of issue of marketing authorisation valid throughout the European Union
01/04/2003
Contact address
51368 Leverkusen
Germany

Product information

19/02/2018 Advocate - EMEA/V/C/000076 - II/0039/G

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ENDECTOCIDES

Therapeutic indication

Dogs

For dogs suffering from, or at risk from, mixed parasitic infections:

  • For the treatment and prevention of flea infestation (Ctenocephalides felis),
  • the treatment of biting lice (Trichodectes canis),
  • the treatment of ear mite infestation (Otodectes cynotis), sarcoptic mange (caused by Sarcoptes scabiei var. canis), demodicosis (caused by Demodex canis),
  • the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis),
  • the treatment of circulating microfilariae (Dirofilaria immitis),
  • the treatment of cutaneous dirofilariosis (adult stages of Dirofilaria repens)
  • the prevention of cutaneous dirofilariosis (L3 larvae of Dirofilaria repens),
  • the reduction of circulating microfilariae (Dirofilaria repens),
  • the prevention of angiostrongylosis (L4 larvae and immature adults of Angiostrongylus vasorum),
  • the treatment of Angiostrongylus vasorum and Crenosoma vulpis,
  • the prevention of spirocercosis (Spirocerca lupi),
  • the treatment of Eucoleus (syn. Capillaria) boehmi (adults),
  • the treatment of the eye worm Thelazia callipaeda (adults),
  • the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara canis, Ancylostoma caninum and Uncinaria stenocephala, adults of Toxascaris leonina and Trichuris vulpis).

The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

Cats

For cats suffering from, or at risk from, mixed parasitic infections:

  • For the treatment and prevention of flea infestation (Ctenocephalides felis),
  • the treatment of ear mite infestation (Otodectes cynotis),
  • the treatment of notoedric mange (Notoedres cati),
  • the treatment of the lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (adults),
  • the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis),
  • the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara cati and Ancylostoma tubaeforme).

The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

Ferrets

For ferrets suffering from, or at risk from, mixed parasitic infections:

  • For the treatment and prevention of flea infestation (Ctenocephalides felis),
  • the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis).

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
1 rating